Compare LEDS & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEDS | NOTV |
|---|---|---|
| Founded | 2005 | 1974 |
| Country | Taiwan | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.2M | 12.7M |
| IPO Year | 2010 | 1997 |
| Metric | LEDS | NOTV |
|---|---|---|
| Price | $1.52 | $0.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 6.7K | ★ 549.0K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.12 | 49.64 |
| EPS | ★ N/A | N/A |
| Revenue | $43,009,000.00 | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 729.81 | 511.19 |
| 52 Week Low | $1.41 | $0.25 |
| 52 Week High | $3.37 | $3.35 |
| Indicator | LEDS | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 37.04 | 50.35 |
| Support Level | N/A | $0.26 |
| Resistance Level | $1.63 | $0.65 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 4.72 | 58.86 |
SemiLEDs Corp develops, manufactures, and sells light-emitting diode chips and LED components. The company's products include LED Chips, LED Components, and Lighting Products. Its products are used for general lighting applications, including street lights and commercial, industrial, system, and residential lighting; specialty industrial applications, such as ultraviolet, or Ultraviolet, curing of polymers, LED light therapy in medical/cosmetic applications, counterfeit detection, LED lighting for horticulture applications, architectural lighting and entertainment lighting. Substantial revenue is generated from the sale of LED components products. Geographically, it derives a majority of its revenue from Japan.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.